Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cor Therapeutics Inc. (CORR) -- Ignore unavailable to you. Want to Upgrade?

To: Sonny who wrote (255)	8/19/1998 8:49:00 PM
From: Robert Mayo	Read Replies (1) \| Respond to of 712

"What gives Robert?" Good question. No good answers. I do know that one major biotech fund dumped a lot of biotech stocks earlier this summer in favor of owning big pharmas. Sorry I can't remember the name, but it was (is) managed by one of the Stansky brothers. Anyway, CORR was one of the stocks that was sold. I heard a short piece on CNBC the other day where a WSJ reporter (Ron Wilson?) was interviewed about heart drugs. CORR got favorable mention. None of this explains why CORR is doing so badly of course. I guess it's just getting hammered like a lot of biotechs. The whole sector is pretty much out of favor, and investors are throwing out the baby with the bath water right now. Hopefully, things will turn around this fall as we start the biotech conference season. Robust Integrilin sales would help too. We should start getting some useful sales data fairly soon. Bob